After Novo Nordisk (NVO) announced that the kidney outcomes trial FLOW demonstrated a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events, or MACE, and death of 24%, RBC Capital said the results, while “encouraging,” are shy of the at least 30% expectation. The FLOW trial is the only ongoing designated kidney outcome trial with a GLP-1s and these results make it unclear how much of a benefit GLP-1s will provide in addition to SGLT2 inhibitors, says the firm, which calls the FLOW results positive for Outset Medical (OM). The firm maintains a Sector Perform rating and $5 price target on Outset shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OM:
- Outset Medical affirms FY24 revenue view of $145M-$153M, consensus $148.8M
- Outset Medical reports Q4 EPS (59c), consensus (61c)
- Outset Medical CCO Steve Williamson to Depart for CEO Role
- Outset Medical downgraded to Sector Perform from Outperform at RBC Capital
- Outset Medical sees Q4 revenue $30.5M, consensus 30.13M